Skip to content

KAMADA LTD

KMDA

CIK 0001567529 · Pharmaceutical Preparations · Nasdaq

← back to feed
Revenue (TTM)
$177.52M
−98.2% YoY FY Dec 2025
Net Income (TTM)
$20.5M
+39.7% YoY FY Dec 2025
EPS Diluted (TTM)
$0.36
+40.0% YoY FY Dec 2025
Gross Margin
43.2%
FY Dec 2025
Operating Margin
15.8%
FY Dec 2025
Net Margin
11.5%
FY Dec 2025
Free Cash Flow (TTM)
—
FY Dec 2025
Cash
$75.47M
FY Dec 2025
Total Debt
—
FY Dec 2025
Shares Outstanding
57.69M sh
FY Dec 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings